TREATMENT OF CANCERS WITH MUTANT NPM1 WITH MEK INHIBITORS

摘要

The present invention generally concerns treatment of cancer in individuals having at least a mutant NPM1 protein, wherein the treatment includes a compound that downregulates level or inhibits activity of mutant NPM1, including, for example, a MEK inhibitor. In certain aspects, the invention concerns combination therapy with MEK inhibitors and other anti -cancer therapies in individuals having cancer with mutant NPM1.